Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparing ARNI With ACE Inhibitor on Endothelial Function
NCT03119623 · Brigham and Women's Hospital · PHASE4 · withdrawn · last registry update 2018-10-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lost funding prior to study commencing” | – | Registry record, Brigham and Women's Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AGTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-10-01Results posted on the registry: Vanderbilt University, Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide) (NCT02278471)
- 2019-09-17Results posted on the registry: Massachusetts General Hospital, FOLFIRINOX + Losartan (NCT01821729)
- 2019-09-13Results posted on the registry: University of Florida, Losartan (NCT02676466)
- 2019-08-30Phase 3 first posted: Hanmi Pharmaceutical Company Limited, HCP1701 + Losartan (NCT04074551)
- 2019-06-19Phase 3 first posted: Boryung Pharmaceutical Co., Ltd, Fimasartan/Amlodipine (NCT03991442)
- 2019-02-04Results posted on the registry: Alere San Diego, Changes of heart failure medications (NCT02351063)
- 2018-12-04Phase 3 first posted: Travere Therapeutics, Inc., sparsentan + irbesartan (NCT03762850)
- 2018-08-17Results posted on the registry: Vanderbilt University Medical Center, Angiotensin II (NCT00962949)
- 2018-06-12Phase 3 first posted: NHS Greater Glasgow and Clyde, sacubitril/valsartan + Valsartan (NCT03552575)
- 2018-04-10Phase 3 first posted: Travere Therapeutics, Inc., sparsentan + Irbesartan (NCT03493685)
- 2017-10-20Phase 3 first posted: University Hospital, Limoges, Valsartan + Placebo Oral Tablet (NCT03315832)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision